肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

CLIN CANCER RES：BAFF受体抗体治疗耐药性B细胞恶性肿瘤

2018-03-08 MedSci MedSci原创

B细胞恶性肿瘤BAFF受体抗体耐药
关注

单抗类药物如抗CD20 rituximab在B细胞恶性肿瘤中具有疗效，但是许多患者会出现耐药。需要靶向其他靶点的治疗方案以避开耐药机制。CLIN CANCER RES近期发表了一篇文章，作者合成了靶向人B细胞活化因子受体（BAFF-R/TNFRSF13C）的单抗，靶向该靶点在肿瘤治疗中尚未得到成功。

单抗类药物如抗CD20 rituximab在B细胞恶性肿瘤中具有疗效，但是许多患者会出现耐药。需要靶向其他靶点的治疗方案以避开耐药机制。CLIN CANCER RES近期发表了一篇文章，作者合成了靶向人B细胞活化因子受体（BAFF-R/TNFRSF13C）的单抗，靶向该靶点在肿瘤治疗中尚未得到成功。

作者在体内和体外实验中评估了嵌合BAFF-R单抗的单药治疗毒性，利用B细胞瘤肿瘤细胞系，患者原发肿瘤样本和耐药肿瘤样本检测嵌合单抗效果。研究结果表明，嵌合抗体与多个人恶性B细胞系具有高度亲和力，可以诱导针对多种人淋巴瘤和白血病亚型的抗体依赖细胞毒性（ADCC），包括接受过抗CD20治疗后出现复发患者的原发肿瘤。嵌合抗体还可以诱导针对ibrutinib耐药和rituximab不敏感CD20缺陷淋巴瘤的ADCC反应。更重要的是，该抗体在耐药肿瘤免疫缺陷鼠模型中具有显着的抑制肿瘤生长的作用。

文章最后认为，抗BAFF-R抗体治疗具有显着的单药抗肿瘤效果。这类抗体为靶向和治疗耐药性B细胞恶性肿瘤提供了新的治疗策略，需要进一步研究。

原始出处：
Hong Qin,Guowei Wei,et al.Novel BAFF-Receptor Antibody to Natively Folded Recombinant Protein Eliminates Drug-Resistant Human B-cell Malignancies In Vivo.CLIN CANCER RES.March 2018 doi:10.1158/1078-0432.CCR-17-1193

本文系梅斯医学（MedSci）原创编译整理，转载需授权！

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1652573, encodeId=bc3116525e38a, content=<a href='/topic/show?id=ca9831e3f4' target=_blank style='color:#2F92EE;'>#BAFF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3173, encryptionId=ca9831e3f4, topicName=BAFF)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=62ca24296368, createdName=徐岩, createdTime=Sat Dec 22 19:46:00 CST 2018, time=2018-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273232, encodeId=affa12e323215, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3837, encryptionId=310d383ef5, topicName=B细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eba113, createdName=xiaoyeshuang, createdTime=Sat Mar 10 00:46:00 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1506213, encodeId=f78a1506213d8, content=<a href='/topic/show?id=dcc7384545' target=_blank style='color:#2F92EE;'>#B细胞恶性肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3845, encryptionId=dcc7384545, topicName=B细胞恶性肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55409728490, createdName=chenzhuanggui, createdTime=Sat Mar 10 00:46:00 CST 2018, time=2018-03-10, status=1, ipAttribution=)]
    2018-12-22 徐岩

    #BAFF#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1652573, encodeId=bc3116525e38a, content=<a href='/topic/show?id=ca9831e3f4' target=_blank style='color:#2F92EE;'>#BAFF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3173, encryptionId=ca9831e3f4, topicName=BAFF)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=62ca24296368, createdName=徐岩, createdTime=Sat Dec 22 19:46:00 CST 2018, time=2018-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273232, encodeId=affa12e323215, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3837, encryptionId=310d383ef5, topicName=B细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eba113, createdName=xiaoyeshuang, createdTime=Sat Mar 10 00:46:00 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1506213, encodeId=f78a1506213d8, content=<a href='/topic/show?id=dcc7384545' target=_blank style='color:#2F92EE;'>#B细胞恶性肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3845, encryptionId=dcc7384545, topicName=B细胞恶性肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55409728490, createdName=chenzhuanggui, createdTime=Sat Mar 10 00:46:00 CST 2018, time=2018-03-10, status=1, ipAttribution=)]
    2018-03-10 xiaoyeshuang

    #B细胞#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1652573, encodeId=bc3116525e38a, content=<a href='/topic/show?id=ca9831e3f4' target=_blank style='color:#2F92EE;'>#BAFF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3173, encryptionId=ca9831e3f4, topicName=BAFF)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=62ca24296368, createdName=徐岩, createdTime=Sat Dec 22 19:46:00 CST 2018, time=2018-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273232, encodeId=affa12e323215, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3837, encryptionId=310d383ef5, topicName=B细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eba113, createdName=xiaoyeshuang, createdTime=Sat Mar 10 00:46:00 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1506213, encodeId=f78a1506213d8, content=<a href='/topic/show?id=dcc7384545' target=_blank style='color:#2F92EE;'>#B细胞恶性肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3845, encryptionId=dcc7384545, topicName=B细胞恶性肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55409728490, createdName=chenzhuanggui, createdTime=Sat Mar 10 00:46:00 CST 2018, time=2018-03-10, status=1, ipAttribution=)]
    2018-03-10 chenzhuanggui

    #B细胞恶性肿瘤#

    0